title: Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.
abstract: BACKGROUND
  The incidence of lung cancer and the cost of drug treatment have increased dramatically in the last decade. This article examines the costs of new target agents, such as tyrosine kinase inhibitors (TKIs) and anti-angiogenic drugs.
  
  
  METHODS
  This study uses PubMed research to focus on the topics of lung cancer, economics, and new targeted therapies.
  
  
  RESULTS
  The published papers only addressed TKIs and anti-angiogenic antibodies. For gefitinib, the results favored a clinical-based selection, despite the low number of studies. Erlotinib was studied in second line and as a maintenance treatment (with the studies reaching opposite conclusions in terms of cost-effectiveness). Economic analyses were not in favor of bevacizumab, but the studies on this topic were very heterogeneous.
  
  
  CONCLUSIONS
  The economic impact of a drug depends on the health care system organization. Future clinical trials must include economic analyses, particularly with TKIs in the first line.
authors: Service de Pathologie Respiratoire et d'Allergologie, CHU Dupuytren, Limoges, France ; Inserm, U707, Paris, France.
authors: A
authors: A
authors: Vergnenègre
authors: I
authors: I
authors: Borget
authors: C
authors: C
authors: Chouaid
keywords: anti-angiogenic; bevacizumab; lung cancer; new target agents; tyrosine kinase inhibitors
references: Curr Med Res Opin. 2007 Jul;23(7):1509-15
references: 17559745
references: Lung Cancer. 2010 Aug;69 Suppl 1:S24-30
references: 20727459
references: Value Health. 2010 Sep-Oct;13(6):743-9
references: 20561327
references: J Int Med Res. 2010 Jan-Feb;38(1):9-21
references: 20233509
references: Lung Cancer. 2008 Sep;61(3):405-15
references: 18295368
references: Ann Oncol. 2011 Aug;22(8):1805-11
references: 21273345
references: Value Health. 2009 Jan-Feb;12(1):20-7
references: 18647257
references: J Thorac Oncol. 2011 Dec;6(12):2097-103
references: 22052223
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: J Med Econ. 2008;11(3):383-96
references: 19450094
references: Lung Cancer. 2012 Jun;76(3):472-7
references: 22226627
references: Rev Mal Respir. 2008 Nov;25(9):1096-103
references: 19106905
references: Clinicoecon Outcomes Res. 2012;4:31-7
references: 22347803
references: Health Technol Assess. 2009 Jun;13 Suppl 1:41-7
references: 19567213
references: J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
references: 21228314
references: Clinicoecon Outcomes Res. 2012;4:237-43
references: 22969300
references: Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33
references: 21585705
references: Pharmacoeconomics. 2011 Dec;29(12):1051-62
references: 21967156
references: Clin Transl Oncol. 2011 Jul;13(7):460-71
references: 21775273
references: Asia Pac J Clin Oncol. 2012 Mar;8(1):53-61
references: 22369444
references: Eur Respir J. 2012 Jan;39(1):172-9
references: 21659409
references: Lung Cancer. 2012 Jun;76(3):465-71
references: 22153602
references: Lung Cancer. 2006 Jan;51(1):115-21
references: 16188343
references: Value Health. 2011 Jan;14(1):41-52
references: 21211485
references: Lancet Oncol. 2010 Jun;11(6):521-9
references: 20493771
references: Lung Cancer. 2010 Aug;69 Suppl 1:S4-10
references: 20727460
references: Lung Cancer. 2010 Aug;69 Suppl 1:S11-7
references: 20727457
references: Pharmacoeconomics. 2009;27(2):113-25
references: 19254045
references: Health Technol Assess. 2010 Oct;14(Suppl. 2):71-9
references: 21047494
references: J Natl Cancer Inst. 2008 Jun 18;100(12):888-97
references: 18544740
references: Pharmacoeconomics. 2012 Jan;30(1):17-34
references: 22201521
references: J Natl Cancer Inst. 2010 Mar 3;102(5):298-306
references: 20160168
references: Cancer. 2012 Feb 15;118(4):1032-9
references: 21792863
references: Clinicoecon Outcomes Res. 2012;4:201-8
references: 22870040
references: Curr Treat Options Oncol. 2011 Mar;12(1):1-11
references: 21267683
references: Lancet Oncol. 2012 Mar;13(3):239-46
references: 22285168